Results 161 to 170 of about 64,289 (310)

Correction: Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016

open access: yesBMC Infectious Diseases
Michaela J. Day   +7 more
doaj   +1 more source

Need for Treatment of Gonorrhea to be Effective against Chlamydia trachomatis

open access: hybrid, 1992
William Bowie   +5 more
openalex   +1 more source

A rapid molecular test for gonorrhea and chlamydia compared to Gram stain for symptomatic patients in a specialized STI clinic: a randomized controlled trial. [PDF]

open access: yesSex Transm Dis
Jarolimova J   +19 more
europepmc   +1 more source

Beyond the Barrier: Epithelial Cells as Immune Sentinels in the Female Genital Tract

open access: yesAmerican Journal of Reproductive Immunology, Volume 95, Issue 5, May 2026.
ABSTRACT Epithelial cells (ECs) of the female genital tract (FGT) serve as an essential barrier and the first line of defense against sexually transmitted pathogens. Beyond providing a physical barrier, these cells actively contribute to immune responses through pathogen recognition, cytokine release, and modulation of adaptive immune responses ...
Lauren Jirik   +3 more
wiley   +1 more source

Assessing the Impact of Female Genital Mutilation/Cutting on Genital Inflammation and Microbiota Among Kenyan Female Sex Workers

open access: yesAmerican Journal of Reproductive Immunology, Volume 95, Issue 5, May 2026.
ABSTRACT Problem Female genital mutilation/cutting (FGM/C) is harmful to physical, mental, and reproductive health, though the effect of this practice on a woman's HIV susceptibility is poorly understood. Despite the known associations of FGM/C with short‐term vaginal epithelial damage, neither genital inflammation nor the genital microbiome have been ...
James Pollock   +19 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

Age-Period-Cohort analysis of gonorrhea surveillance data in Eastern China from 2005 to 2024. [PDF]

open access: yesBMC Infect Dis
Fang Z   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy